JP5930311B2 - 麻酔薬製剤 - Google Patents

麻酔薬製剤 Download PDF

Info

Publication number
JP5930311B2
JP5930311B2 JP2012549208A JP2012549208A JP5930311B2 JP 5930311 B2 JP5930311 B2 JP 5930311B2 JP 2012549208 A JP2012549208 A JP 2012549208A JP 2012549208 A JP2012549208 A JP 2012549208A JP 5930311 B2 JP5930311 B2 JP 5930311B2
Authority
JP
Japan
Prior art keywords
cyclodextrin
alphaxalone
anesthetic
rats
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012549208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517299A5 (https=
JP2013517299A (ja
Inventor
マーガレット グッドチャイルド，ジュリエット
マーガレット グッドチャイルド，ジュリエット
スタンリー グッドチャイルド，コリン
スタンリー グッドチャイルド，コリン
ジェイムズ ボイド，ベンジャミン
ジェイムズ ボイド，ベンジャミン
Original Assignee
ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド
ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド, ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド filed Critical ドローブリッジ ファーマシューティカルズ プロプライエタリー リミテッド
Publication of JP2013517299A publication Critical patent/JP2013517299A/ja
Publication of JP2013517299A5 publication Critical patent/JP2013517299A5/ja
Application granted granted Critical
Publication of JP5930311B2 publication Critical patent/JP5930311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012549208A 2010-01-21 2011-01-19 麻酔薬製剤 Active JP5930311B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (3)

Publication Number Publication Date
JP2013517299A JP2013517299A (ja) 2013-05-16
JP2013517299A5 JP2013517299A5 (https=) 2014-03-06
JP5930311B2 true JP5930311B2 (ja) 2016-06-08

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549208A Active JP5930311B2 (ja) 2010-01-21 2011-01-19 麻酔薬製剤

Country Status (27)

Country Link
US (2) US8697678B2 (https=)
EP (1) EP2525798B1 (https=)
JP (1) JP5930311B2 (https=)
KR (1) KR101747476B1 (https=)
CN (1) CN102802635B (https=)
AU (1) AU2011207103B2 (https=)
BR (1) BR112012017800B1 (https=)
CA (1) CA2786762C (https=)
CL (1) CL2012002032A1 (https=)
CY (1) CY1119947T1 (https=)
DK (1) DK2525798T3 (https=)
ES (1) ES2646829T3 (https=)
GB (2) GB2484244B (https=)
HR (1) HRP20171699T1 (https=)
HU (1) HUE035441T2 (https=)
LT (1) LT2525798T (https=)
NO (1) NO2525798T3 (https=)
NZ (1) NZ601255A (https=)
PL (1) PL2525798T3 (https=)
PT (1) PT2525798T (https=)
RS (1) RS56576B1 (https=)
RU (1) RU2574022C2 (https=)
SG (1) SG181997A1 (https=)
SI (1) SI2525798T1 (https=)
SM (1) SMT201700518T1 (https=)
WO (1) WO2011088503A1 (https=)
ZA (1) ZA201205370B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) * 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
MX2015002252A (es) * 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
EP3818068B1 (en) * 2018-07-03 2025-10-29 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
JP7780431B2 (ja) 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
CN101583620B (zh) * 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法

Also Published As

Publication number Publication date
GB2484244B (en) 2012-10-31
HRP20171699T1 (hr) 2018-01-26
US8697678B2 (en) 2014-04-15
GB2491491A (en) 2012-12-05
CN102802635B (zh) 2014-07-30
US20120316146A1 (en) 2012-12-13
NO2525798T3 (https=) 2018-01-06
BR112012017800A2 (en) 2018-07-10
PT2525798T (pt) 2017-11-15
WO2011088503A1 (en) 2011-07-28
AU2011207103B2 (en) 2013-03-21
US8975245B2 (en) 2015-03-10
NZ601255A (en) 2013-09-27
EP2525798A1 (en) 2012-11-28
CL2012002032A1 (es) 2012-12-21
LT2525798T (lt) 2018-01-10
ES2646829T3 (es) 2017-12-18
EP2525798B1 (en) 2017-08-09
HUE035441T2 (en) 2018-05-02
RU2012134321A (ru) 2014-02-27
GB201201842D0 (en) 2012-03-21
JP2013517299A (ja) 2013-05-16
CY1119947T1 (el) 2018-12-12
US20140066417A1 (en) 2014-03-06
EP2525798A4 (en) 2014-02-19
CA2786762A1 (en) 2011-07-28
KR101747476B1 (ko) 2017-06-14
PL2525798T3 (pl) 2018-05-30
SG181997A1 (en) 2012-08-30
KR20120136347A (ko) 2012-12-18
GB201210657D0 (en) 2012-08-01
SMT201700518T1 (it) 2018-01-11
HK1169031A1 (en) 2013-01-18
AU2011207103A1 (en) 2012-07-26
BR112012017800A8 (pt) 2018-08-14
SI2525798T1 (en) 2018-01-31
GB2484244A (en) 2012-04-04
RS56576B1 (sr) 2018-02-28
BR112012017800B1 (pt) 2020-12-08
CN102802635A (zh) 2012-11-28
CA2786762C (en) 2017-12-05
ZA201205370B (en) 2013-09-25
DK2525798T3 (da) 2017-11-20
GB2491491B (en) 2014-07-30
RU2574022C2 (ru) 2016-01-27

Similar Documents

Publication Publication Date Title
JP5930311B2 (ja) 麻酔薬製剤
EP2785352B1 (en) Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
CN107810000B (zh) 来氟米林的可注射药物组合物
EP3556349B1 (en) Parenteral liquid preparation comprising carbamate compound
ES2657937T3 (es) Métodos y formulaciones de meclizina inyectables
AU2013200895C1 (en) Anaesthetic formulation
AU2014200491A1 (en) Anaesthetic formulation
HK1252534B (zh) 来氟米林的可注射药物组合物
HK1150553B (en) Pharmaceutical preparation comprising permethylated cyclodextrin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160420

R150 Certificate of patent or registration of utility model

Ref document number: 5930311

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250